logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 8652 352524; +7 8652 353229.

Fax
+7 8652 352524.

E-mail
medvestnik@stgmu.ru

Analysis of the pathogenetic relationship between IL18, IL18BP, and IL37 and vasoactive substances (AT II, ET-1, NO, ADMA, SDMA, eNOS, iNOS, NT-proСNP AND NT-proВNP) in essential arterial hyperte

[Original research] [Experimental medicine]
Olga Alexandrovna Radaeva; Andrey Semenovich Simbirtsev;

The objective of this study is to analyze the relationship between serum concentrations of IL18, IL18BP, and IL37 and vasoactive substances (AT II, ET-1, NO, etc.) in patients with Stage II EAH. SDMA growth in Stage II EAH patients is linked with the ratio of three members of the IL1 family in the blood serum: IL18, IL18BP and IL37. An increase of IL18 of more than 358 pg/mL against a background of IL18BP and IL37 no less than 6200 pg/mL and 74 pg/mL, respectively, correlates with a growth in SDMA and reduction in NO that is typical for patients with Stage II EAH lasting 10–14 years without antihypertensive therapy. Treatment with antihypertension therapy exhibits an increase in IL37 and IL18ВР concentrations in the serum, as well as synergistic effects in the form of IL18 suppression and an additional reduction in SDMA amidst NO growth.

Download

References:
1. Wenzel U., Turner J. E., Krebs C., Kurts C., Harrison D. G. [et al.]. Immune Mechanisms in Arterial Hypertension. Journal of the American Society of Nephrology. 2016;27(3):677-686. https://doi.org/10.1681/ASN.2015050562
2. Nosalski R., McGinnigle E., Siedlinski M., Guzik T. J. Novel Immune Mechanisms in Hypertension and Cardiovascular Risk. Current Cardiovascular Risk Reports. 2017;11(4):12. https://doi.org/10.1007/s12170-017-0537-6
3. Zhan Q., Zeng Q., Song R., Zhai Y., Xu D. [et al.]. IL-37 suppresses MyD88-mediated inflammatory responses in human aortic valve interstitial cells. Molecular Medicine. 2017;4(23):83-91. https://doi.org/10.2119/molmed.2017.00022
4. Zhu R., Sun H., Yu K. Interleukin-37 and Dendritic Cells Treated With Interleukin-37 Plus Troponin I Ameliorate Cardiac Remodeling After Myocardial Infarction. Journal of the American Heart Association. 2016;5(12):e004406. https://doi.org/10.1161/JAHA.116.004406
5. Dinarello C. A., Novick D., Kim S, Kaplanski G. Interleukin-18 and IL-18 Binding Protein. Frontiers in Immunology. 2013;4:289. https://doi.org/10.3389/fimmu.2013.00289
6. Yerramilli M., Farace G., Quinn J., Yerramilli M. Kidney Disease and the Nexus of Chronic Kidney Disease and Acute Kidney Injury: The Role of Novel Biomarkers as Early and Accurate Diagnostics. Veterinary Clinics: Small Animal Practice. 2016;46(6):961-93. https://doi.org/10.1016/j.cvsm.2016.06.011

Keywords: IL-18, IL-18BP, IL-37, essential hypertension


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy